

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PHARMACOSMOS A/S,
Petitioner,

v.

LUITPOLD PHARMACEUTICALS, INC.,
Patent Owner.

Cases¹ IPR2015-01490; Patent 7,754,702 B2
IPR2015-01493; Patent 8,431,549 B2

DECLARATION OF DR. ADRIANA MANZI

¹ The word-for-word identical paper is filed in each proceeding identified in the heading.

TABLE OF CONTENTS

I.	QUALIFICATIONS	1
II.	OVERVIEW	3
III.	THE '702 and '549 PATENTS	8
IV.	PERSON OF ORDINARY SKILL IN THE ART	11
V.	PATENT OWNER RESPONSE	12
	A. “substantially non-immunogenic carbohydrate component”	13
	B. “iron sorbitol complex” does not include “iron polyglucose sorbitol carboxymethyl ether complex”	16
	C. “iron carboxymaltose complex”	19
	D. van Zyl-Smit.....	20
	1. van Zyl-Smit does not teach a “substantially non-immunogenic carbohydrate component”	20
	2. van Zyl-Smit’s sample size is not large enough to demonstrate “substantial non-immunogenicity”	21
	3. The results of van Zyl-Smit are not generalizable to iron polymaltose	22
	E. Funk.....	23
	F. Groman.....	26
	1. Groman’s complex is not an “iron sorbitol complex”	26
	2. Groman does not teach a rate of administration of “about 15 minutes or less”	27
	3. The complexes of Groman and Geisser are not “structurally analogous”	28

VI. PATENT OWNER’S MOTION TO AMEND30

 A. State of the Art32

 B. Prior Art of Record.....35

 1. Art Relating Specifically to Iron Dextran Complexes.....35

 2. Art Relating Specifically to Restless Leg Syndrome36

 3. Art Relating Specifically to “Ferumoxytol”37

 4. Art Relating Specifically to Iron Polymaltose Complexes.....39

 5. Art Relating to Other Iron Carbohydrate Complexes.....40

 6. Other.....43

VII. CONCLUSION.....44

I, Dr. Adriana E. Manzi, declare as follows:

I. QUALIFICATIONS

1. I have been retained by Foley and Lardner LLP to act as an expert witness in a matter on behalf of its client, Luitpold Pharmaceuticals, Inc. (“Patent Owner”).

The matter is *Inter Partes* Review No. 2015-01490 of United States Patent No. 7,754,702 by Helenek (“the ’702 Patent”) and *Inter Partes* Review No. 2015-01493 of United States Patent No. 8,431,549 by Helenek (“the ’549 Patent”) brought by Pharmacosmos A/S (“Petitioner”).

2. I am being compensated for my time in connection with this matter. My compensation is not dependent on the outcome of this matter.

3. I earned a “Licenciature” degree (five-year program equivalent to a combination of Bachelor and Master of Science degree focusing on Food Sciences and Industrial Chemistry) and a Ph.D. degree in organic chemistry from the University of Buenos Aires, in Argentina. My Doctoral Thesis focused on the study of plant polysaccharides and the relationship between their structure and properties. I conducted four years of postdoctoral research in biochemistry and glycobiology at the Cancer Center, Department of Medicine, University of California San Diego followed by seven years as an Adjunct Assistant Professor. In parallel, I was the Director of the Glycobiology Core Facility, that conducted

carbohydrate analysis for University of California investigators as well as external institutions and the private sector.

4. A copy of my *curriculum vitae* (“CV”) is Exhibit 2057. As reflected in my CV, I have significant expertise in carbohydrate chemistry and biochemistry (glycobiology) as well as in the development of pharmaceutical products. I have worked on research on plant and animal polysaccharides as well as carbohydrate-containing natural molecules from 1978 to 1998. From 1998 to 2006, I worked on the development of carbohydrate therapeutics (for inflammation and xenotransplantation) at positions of increasing responsibilities at the Baxter International group. During this period I worked on glycoconjugates (molecules containing carbohydrates and peptides or lipids), polysaccharide solutions for dialysis (i.e., icodextrin based), and polysaccharide vaccines as well as natural and recombinant glycoproteins for different indications. I have been involved in many projects encompassing carbohydrate-containing molecules, including the evaluation of antigenicity of these molecules, and have encountered many issues related to the isolation of natural polysaccharides. Ex. 2057, pp. 3-5.

5. Since 2006, as part of my consulting work, I supported many projects related to carbohydrate-containing molecules from polysaccharides to glycoproteins and glycolipids. My work includes all CMC (chemistry manufacturing and controls) aspects of carbohydrate-containing molecules,

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.